Market research
KLDO Kaleido Biosciences Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4K
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- Not available
- Beta
- 40.04
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4833471000
- Market cap
- 4K
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- Not available
- Beta
- 40.04
About
About Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KLDO discussion.
5 years, 4 months ago
Kaleido Biosciences, Inc is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 79.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 277.6.
Kaleido Biosciences, Inc's total revenue rose by inf% to $243K since the same quarter in the previous year.
Its net income has dropped by 2.6% to $-20M since the same quarter in the previous year.
Finally, its free cash flow grew by 28.2% to $-12M since the same quarter in the previous year.
Based on the above factors, Kaleido Biosciences, Inc gets an overall score of 3/5.